Default company panoramic image

AgilVax, Inc.

Patented platform technology capable of rapidly identifying vaccine components, producing new, effective vaccines and next-gen diagnostics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location St Paul, MN, USA
  • Currency USD
  • Founded June 2011
  • Employees 2
  • Website

Company Summary

AgilVax® Inc. is commercializing a virus-like particle (VLP) based vaccine platform technology under a worldwide, exclusive license. The platform, derived from RNA bacteriophages, is a cost-effective method for developing safe, efficacious vaccines for chronic and infectious diseases. It is the only VLP platform that facilitates both vaccine discovery and implementation. Moreover, it identifies components required to diagnose specific infections.


  • Default avatar
    Joseph Shaw
    Chief Executive Officer

    Mr. Shaw has extensive experience with formulating winning corporate strategies, including vaccine development and negotiation of many substantive strategic partnerships, acquisitions and public offerings. He has broad international and domestic experience in product development, biotechnology start-ups as well as “turn-arounds”.

  • Default avatar
    Sandra Lobo
    Chief Scientific Officer

    Dr. Lobo has a PhD in biochemistry, a degree in Pharmacy and two postdoctoral degrees. She is widely published in the fields of biochemistry, molecular biology and biological and metabolic pathways. She combines an extensive list of publications and patents with extensive commercial experience in the area of vaccine development. She is an adjunct professor at the University of Minnesota, Department of Surgery.


  • Default avatar
    Leonard, Street & Deinard, PPL
    Default avatar
    Brescia Accounting, New Mexico

Previous Investors

  • Default avatar
    Southwest Medical Technology, LLC
    Default avatar
    University of New Mexico
    Default avatar
    Sun Mountain Capital, Sandra Lobo, Joseph Shaw